KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Equity Income (2020 - 2023)

Ginkgo Bioworks Holdings' Equity Income history spans 4 years, with the latest figure at -$1.1 million for Q4 2023.

  • For Q4 2023, Equity Income fell 111.19% year-over-year to -$1.1 million; the TTM value through Sep 2024 reached -$1.1 million, down 113.18%, while the annual FY2023 figure was -$2.6 million, 93.98% up from the prior year.
  • Equity Income reached -$1.1 million in Q4 2023 per DNA's latest filing, down from -$67000.0 in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $59.9 million in Q4 2021 to a low of -$39.7 million in Q3 2021.
  • Average Equity Income over 4 years is -$5.1 million, with a median of -$4.3 million recorded in 2021.
  • The largest YoY upside for Equity Income was 368.11% in 2021 against a maximum downside of 16630.38% in 2021.
  • A 4-year view of Equity Income shows it stood at -$22.3 million in 2020, then soared by 368.11% to $59.9 million in 2021, then tumbled by 83.31% to $10.0 million in 2022, then tumbled by 111.19% to -$1.1 million in 2023.
  • Per Business Quant, the three most recent readings for DNA's Equity Income are -$1.1 million (Q4 2023), -$67000.0 (Q2 2023), and -$1.4 million (Q1 2023).